vesemnogene lantuparvovec

BIOLOGICAL2 trials

Sponsors

Lantu Biopharma

Conditions

Spinal Muscular AtrophySpinal Muscular Atrophy (SMA)

Phase 1

An Open Label Study of Gene Therapy Product (Vesemnogene Lantuparvovec) in Spinal Muscular Atrophy

Active, not recruitingNCT06288230

Lantu BiopharmaSpinal Muscular Atrophy

Start: 2024-10-20End: 2027-10-30Target: 20Updated: 2026-06-15

Phase 3

Real World Clinical Effectiveness & Safety of Vesemnogene Lantuparvovec for Spinal Muscular Atrophy (SMA) in Low-middle Income Countries (LMIC).

RecruitingNCT07265232

Lantu BiopharmaSpinal Muscular Atrophy (SMA)

Start: 2025-10-15End: 2030-10-15Target: 15Updated: 2025-12-04

Related Papers

Twelve-Month Outcomes of Intrathecal Vesemnogene Lantuparvovec for Spinal Muscular Atrophy in Children Younger than 24 Months in Low- and Middle- Income Countries

medRxiv2026-05-30